Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10555-021-09972-4.pdf
Reference75 articles.
1. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. (2016). Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study. Journal of Clinical Oncology, 34(21), 2460–2467.
2. Nanda R, Specht J, Dees C, Berger R, Gupta S, Geva R, et al. (2016). KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple negative breast cancer. San Antonio Breast Cancer Symposium 2016. Cancer Research, 77(suppl_4): P6-10-03.
3. Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, et al. (2017). Evaluation of dosing strategy for pembrolizumab for oncology indications. Journal for Immunotherapy of Cancer, 5, 43.
4. Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. (2019). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Annals of Oncology, 30(3), 397–404.
5. Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. (2019). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Annals of Oncology, 30(3), 405–411.
Cited by 76 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC;npj Breast Cancer;2024-09-12
2. Expression and clinical significance of CLDN7 and its immune-related cells in breast cancer;Diagnostic Pathology;2024-08-22
3. Biosynthetic MnSe nanobomb with low Mn content activates the cGAS-STING pathway and induces immunogenic cell death to enhance antitumour immunity;Acta Biomaterialia;2024-08
4. 19F MRI/CEUS Dual Imaging‐Guided Sonodynamic Therapy Enhances Immune Checkpoint Blockade in Triple‐Negative Breast Cancer;Advanced Science;2024-07-25
5. Loss of tumor suppressors promotes inflammatory tumor microenvironment and enhances LAG3+T cell mediated immune suppression;Nature Communications;2024-07-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3